SAN FRANCISCO ( TheStreet) -- The biotech hordes should be in a jollier mood when they land here Monday for the J.P. Morgan Healthcare Conference.The biotech sector enters the new year at least partially recovered from the thrashing inflicted on stocks that began in the fall of 2008 and didn't end until last March. Since then, stocks prices have rebounded -- not back to their previous highs, but they're getting there. Perhaps more importantly, biotech companies were able to raise a lot of cash in the second half of last year to stave off extinction.
J.P. Morgan Healthcare Confab: Preview
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.